Search
CAMP4 Therapeutics Corp
CAMPAdd to Watchlist
4.430USD
+0.090+2.07%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
207.68MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.07%
5 Days
+5.48%
1 Month
+3.02%
6 Months
-26.17%
Year to Date
-27.73%
1 Year
+209.79%
Key Figures
4.380Open
4.500High
114.97KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.25%Turnover Ratio
4.340Prev. Close
4.180Low
336.69KTurnover
LossP/E Static
3.54P/B
0.00%Div Yield TTM
-102.60%ROA
7.75052wk High
0.24Volume Ratio
-51.79MNet Profit
46.88MShares
-2.3461EPS TTM
--Beta
-209.28%ROE
1.30552wk Low
7.37%Amplitude
100.00%Gross Margin
207.68MMarket Cap
0.13Reward/Risk
7.18%Risk Rate
TradingKey Stock Score of CAMP4 Therapeutics Corp
Currency: USD Updated: 2026-07-02Key Insights
CAMP4 Therapeutics Corp's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 130 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CAMP4 Therapeutics Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
CAMP4 Therapeutics Corp Highlights
StrengthsRisks
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 899.43% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.50M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.50M.
Fairly Valued
The company’s latest PE is -1.89, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 42.58M shares, increasing 25.65% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 18.15K shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
8.500
Target Price
+95.85%
Upside Space
CAMP4 Therapeutics Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
CAMP4 Therapeutics Corp Info
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
Ticker SymbolCAMP
CompanyCAMP4 Therapeutics Corp
CEOMandel-Brehm (Josh)
Websitehttps://www.camp4tx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of CAMP4 Therapeutics Corp (CAMP)?
The current price of CAMP4 Therapeutics Corp (CAMP) is 4.43.
What is the symbol of CAMP4 Therapeutics Corp?
The ticker symbol of CAMP4 Therapeutics Corp is CAMP.
What is the 52-week high of CAMP4 Therapeutics Corp?
The 52-week high of CAMP4 Therapeutics Corp is 7.75.
What is the 52-week low of CAMP4 Therapeutics Corp?
The 52-week low of CAMP4 Therapeutics Corp is 1.30.
What is the market capitalization of CAMP4 Therapeutics Corp?
The market capitalization of CAMP4 Therapeutics Corp is 207.68M.
Is CAMP4 Therapeutics Corp (CAMP) currently rated as Buy, Hold, or Sell?
According to analysts, CAMP4 Therapeutics Corp (CAMP) has an overall rating of Buy, with a price target of 8.50.
What is the Earnings Per Share (EPS TTM) of CAMP4 Therapeutics Corp (CAMP)?
The Earnings Per Share (EPS TTM) of CAMP4 Therapeutics Corp (CAMP) is -2.65.